Armata Pharmaceuticals, Inc. (ARMP)
USD 1.95
(-2.5%)
USD 1.95
(-2.5%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 120.37 Million USD | 146.59% |
| 2022 | 48.81 Million USD | 28.5% |
| 2021 | 37.98 Million USD | 188.89% |
| 2020 | 13.15 Million USD | 359.31% |
| 2019 | 2.86 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | -100.0% |
| 2016 | 803 Thousand USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | -100.0% |
| 2012 | 3.64 Million USD | 0.0% |
| 2008 | - USD | -100.0% |
| 2007 | 336 Thousand USD | -80.22% |
| 2006 | 1.69 Million USD | -79.61% |
| 2005 | 8.33 Million USD | -27.24% |
| 2004 | 11.45 Million USD | -8.52% |
| 2003 | 12.51 Million USD | -42.56% |
| 2002 | 21.79 Million USD | 23.04% |
| 2001 | 17.71 Million USD | 439.26% |
| 2000 | 3.28 Million USD | -0.48% |
| 1999 | 3.3 Million USD | 57.14% |
| 1998 | 2.1 Million USD | -16.0% |
| 1997 | 2.5 Million USD | -26.47% |
| 1996 | 3.4 Million USD | 3.03% |
| 1995 | 3.3 Million USD | 13.79% |
| 1994 | 2.9 Million USD | 141.67% |
| 1993 | 1.2 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 146.14 Million USD | -12.96% |
| 2024 Q1 | 167.9 Million USD | 39.49% |
| 2023 Q4 | 120.37 Million USD | 5.93% |
| 2023 FY | 120.37 Million USD | 146.59% |
| 2023 Q2 | 26.35 Million USD | -65.92% |
| 2023 Q3 | 113.62 Million USD | 331.2% |
| 2023 Q1 | 77.33 Million USD | 58.42% |
| 2022 Q4 | 48.81 Million USD | 23.75% |
| 2022 Q2 | 38.93 Million USD | 1.29% |
| 2022 FY | 48.81 Million USD | 28.5% |
| 2022 Q1 | 38.44 Million USD | 1.2% |
| 2022 Q3 | 39.44 Million USD | 1.3% |
| 2021 Q3 | 12.31 Million USD | -5.81% |
| 2021 FY | 37.98 Million USD | 188.89% |
| 2021 Q2 | 13.07 Million USD | -0.25% |
| 2021 Q1 | 13.1 Million USD | -0.33% |
| 2021 Q4 | 37.98 Million USD | 208.5% |
| 2020 Q4 | 13.15 Million USD | 0.88% |
| 2020 Q2 | 12.66 Million USD | 396.16% |
| 2020 Q3 | 13.03 Million USD | 2.95% |
| 2020 Q1 | 2.55 Million USD | -10.86% |
| 2020 FY | 13.15 Million USD | 359.31% |
| 2019 Q4 | 2.86 Million USD | -9.14% |
| 2019 Q3 | 3.15 Million USD | -14.31% |
| 2019 Q2 | 3.67 Million USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 FY | 2.86 Million USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q3 | 305 Thousand USD | -49.67% |
| 2017 Q2 | 606 Thousand USD | 1.34% |
| 2017 FY | - USD | -100.0% |
| 2017 Q4 | - USD | -100.0% |
| 2017 Q1 | 598 Thousand USD | -25.53% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | 803 Thousand USD | 0.0% |
| 2016 FY | 803 Thousand USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | -100.0% |
| 2012 FY | 3.64 Million USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 FY | - USD | -100.0% |
| 2008 Q1 | 335 Thousand USD | -0.3% |
| 2008 Q2 | 335 Thousand USD | 0.0% |
| 2008 Q3 | - USD | -100.0% |
| 2008 Q4 | - USD | 0.0% |
| 2007 Q1 | 1.68 Million USD | -0.94% |
| 2007 FY | 336 Thousand USD | -80.22% |
| 2007 Q2 | 1.67 Million USD | -0.3% |
| 2007 Q4 | 336 Thousand USD | -33.33% |
| 2007 Q3 | 504 Thousand USD | -69.96% |
| 2006 FY | 1.69 Million USD | -79.61% |
| 2006 Q1 | 8.27 Million USD | -0.66% |
| 2006 Q2 | 8.22 Million USD | -0.68% |
| 2006 Q4 | 1.69 Million USD | -79.27% |
| 2006 Q3 | 8.19 Million USD | -0.29% |
| 2005 Q4 | 8.33 Million USD | -0.63% |
| 2005 FY | 8.33 Million USD | -27.24% |
| 2005 Q3 | 8.38 Million USD | -23.38% |
| 2005 Q1 | 11.1 Million USD | -2.99% |
| 2005 Q2 | 10.94 Million USD | -1.49% |
| 2004 Q1 | 12.31 Million USD | -1.61% |
| 2004 Q2 | 12.38 Million USD | 0.56% |
| 2004 Q3 | 11.57 Million USD | -6.5% |
| 2004 Q4 | 11.45 Million USD | -1.11% |
| 2004 FY | 11.45 Million USD | -8.52% |
| 2003 Q1 | 22.1 Million USD | 1.45% |
| 2003 Q4 | 12.51 Million USD | -1.22% |
| 2003 Q2 | 22.1 Million USD | -0.03% |
| 2003 Q3 | 12.67 Million USD | -42.67% |
| 2003 FY | 12.51 Million USD | -42.56% |
| 2002 Q1 | 18.08 Million USD | 2.13% |
| 2002 FY | 21.79 Million USD | 23.04% |
| 2002 Q2 | 23.12 Million USD | 27.84% |
| 2002 Q4 | 21.79 Million USD | -8.22% |
| 2002 Q3 | 23.74 Million USD | 2.69% |
| 2001 Q1 | 3.13 Million USD | -4.45% |
| 2001 Q4 | 17.71 Million USD | 33.0% |
| 2001 Q3 | 13.31 Million USD | 175.84% |
| 2001 Q2 | 4.82 Million USD | 53.84% |
| 2001 FY | 17.71 Million USD | 439.26% |
| 2000 Q2 | 3.36 Million USD | 3.54% |
| 2000 Q3 | 3.62 Million USD | 7.86% |
| 2000 Q4 | 3.28 Million USD | -9.43% |
| 2000 FY | 3.28 Million USD | -0.48% |
| 2000 Q1 | 3.24 Million USD | -1.6% |
| 1999 Q2 | 2.7 Million USD | 17.39% |
| 1999 FY | 3.3 Million USD | 57.14% |
| 1999 Q4 | 3.3 Million USD | 43.48% |
| 1999 Q1 | 2.3 Million USD | 9.52% |
| 1999 Q3 | 2.3 Million USD | -14.81% |
| 1998 Q1 | 2.8 Million USD | 12.0% |
| 1998 Q2 | 2.6 Million USD | -7.14% |
| 1998 Q3 | 2.3 Million USD | -11.54% |
| 1998 Q4 | 2.1 Million USD | -8.7% |
| 1998 FY | 2.1 Million USD | -16.0% |
| 1997 FY | 2.5 Million USD | -26.47% |
| 1997 Q1 | 3.3 Million USD | -2.94% |
| 1997 Q2 | 3.1 Million USD | -6.06% |
| 1997 Q3 | 2.8 Million USD | -9.68% |
| 1997 Q4 | 2.5 Million USD | -10.71% |
| 1996 Q1 | 3.6 Million USD | 9.09% |
| 1996 FY | 3.4 Million USD | 3.03% |
| 1996 Q4 | 3.4 Million USD | 3.03% |
| 1996 Q2 | 3.5 Million USD | -2.78% |
| 1996 Q3 | 3.3 Million USD | -5.71% |
| 1995 Q4 | 3.3 Million USD | 22.22% |
| 1995 FY | 3.3 Million USD | 13.79% |
| 1995 Q3 | 2.7 Million USD | -3.57% |
| 1995 Q1 | 2.9 Million USD | 0.0% |
| 1995 Q2 | 2.8 Million USD | -3.45% |
| 1994 FY | 2.9 Million USD | 141.67% |
| 1994 Q4 | 2.9 Million USD | 38.1% |
| 1994 Q2 | 2.2 Million USD | 0.0% |
| 1994 Q3 | 2.1 Million USD | -4.55% |
| 1993 FY | 1.2 Million USD | 0.0% |
| 1993 Q4 | 1.2 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 495 Thousand USD | -24217.374% |
| Ampio Pharmaceuticals, Inc. | 274 Thousand USD | -43831.022% |
| Actinium Pharmaceuticals, Inc. | 2.11 Million USD | -5596.687% |
| Azitra, Inc. | 885.94 Thousand USD | -13486.704% |
| Can-Fite BioPharma Ltd. | 39.99 Thousand USD | -300835.023% |
| Chromocell Therapeutics Corporation | 1.26 Million USD | -9387.856% |
| Calidi Biotherapeutics, Inc. | 7.23 Million USD | -1563.502% |
| CEL-SCI Corporation | 13.57 Million USD | -786.923% |
| iBio, Inc. | 4.46 Million USD | -2598.901% |
| Lineage Cell Therapeutics, Inc. | 2.95 Million USD | -3977.608% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 3.55 Million USD | -3285.011% |
| Navidea Biopharmaceuticals, Inc. | 2.43 Million USD | -4844.781% |
| NovaBay Pharmaceuticals, Inc. | 2.74 Million USD | -4293.102% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | 312.7 Thousand USD | -38393.714% |
| BiomX Inc. | 15.09 Million USD | -697.582% |
| BiomX Inc. | 15.09 Million USD | -697.582% |
| Protalix BioTherapeutics, Inc. | 26.28 Million USD | -358.015% |
| Palatin Technologies, Inc. | 590.33 Thousand USD | -20290.183% |
| Scorpius Holdings, Inc. | 14.04 Million USD | -757.219% |